ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
Promotion
Recombinantタンパク質s ClearClear history
Recombinantタンパク質s CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |Omicron specific antibody Hot |Claudin 18.2 |Cadherin-17
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > LAG-3

LAG-3

概要

Name:Lymphocyte activation gene 3 protein
Target Synonym:Lymphocyte activation gene 3 protein,LAG3,Lymphocyte Activating 3,Lymphocyte-Activation Gene 3,CD223 Antigen,Protein FDC,CD223,LAG-3,FDC,sLAG-3
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:29
Lastest Research Phase:Approved

ライセンス

Project Name Modality Therapeutic Area Indications Stage Right Available
LAG-3 mAb Monospecific antibody Oncology/Cancer Advanced solid tumor Phase I Global

製品リスト製品比較と製品注文

製品> フィルター結果
製品仕様別：
製品カテゴリー別：
種類別：
タグ別：
コンジュゲート：
製造番号 種類 製品説明 構造 純度 特徴
LA3-M82F3 Mouse Biotinylated Mouse LAG-3 / CD223 Protein, Fc,Avitag™ (MALS verified)
LA3-M82F3-structure
LA3-M82F3-sds
LA3-M5253 Mouse Mouse LAG-3 / CD223 Protein, Fc Tag (MALS verified)
LA3-M5253-structure
LA3-M5253-sds
LA3-H82E9 Human Biotinylated Human LAG-3 / CD223 Protein, His,Avitag™ (MALS verified)
LA3-H82E9-structure
LA3-H82E9-sds
LA3-C8258 Cynomolgus Biotinylated Cynomolgus LAG-3 / CD223 Protein, Mouse IgG2a Fc Tag, ultra sensitivity (primary amine labeling)
LA3-C8258-structure
LA3-C8258-sds
LA3-C52H7 Canine Canine LAG-3 / CD223 Protein, His Tag (MALS verified)
LA3-C52H7-structure
LA3-C52H7-sds
LA3-C82H3 Cynomolgus Cynomolgus LAG-3 / CD223 Protein, His Tag
LA3-C82H3-structure
LA3-C82H3-sds
LA3-C82E5 Cynomolgus Biotinylated Cynomolgus LAG-3 / CD223 Protein, His,Avitag™
LA3-C82E5-structure
LA3-C82E5-sds
LA3-M82E5 Mouse Biotinylated Mouse LAG-3 / CD223 Protein, His,Avitag™ (MALS verified)
LA3-M82E5-structure
LA3-M82E5-sds
LA3-H82Fb Human Biotinylated Human LAG-3 / CD223 Protein, Fc,Avitag™ (MALS verified)
LA3-H82Fb-structure
LA3-H82Fb-sds
LA3-H525c Human Human LAG-3 / CD223 Protein, Llama IgG2b Fc Tag, low endotoxin (MALS verified)
LA3-H525c-structure
LA3-H525c-sds
LA3-H522a Human Human LAG-3 / CD223 Protein, His Tag, low endotoxin
LA3-H522a-structure
LA3-H522a-sds
LA3-H82F3 Human Biotinylated Human LAG-3 / CD223 Protein, Mouse IgG2a Fc,Avitag™ (MALS verified)
LA3-H82F3-structure
LA3-H82F3-sds
LA3-M52Ha Marmoset Marmoset LAG-3 / CD223 Protein, His Tag
LA3-M52Ha-structure
LA3-M52Ha-sds
LA3-H52Aa Human Human LAG-3 / CD223 Protein, Mouse IgG2a Fc Tag (MALS verified)
LA3-H52Aa-structure
LA3-H52Aa-sds
LA3-C52A0 Cynomolgus Cynomolgus LAG-3 / CD223 Protein, Mouse IgG2a Fc Tag
LA3-C52A0-structure
LA3-C52A0-sds
LA3-C5252 Cynomolgus Cynomolgus LAG-3 / CD223 Protein, Fc Tag
LA3-C5252-structure
LA3-C5252-sds
LA3-H5255 Human Human LAG3 / CD223 Protein, Fc Tag (MALS Verified)
LA3-H5255-structure
LA3-H5255-sds
LA3-M52H5 Mouse Mouse LAG-3 / CD223 Protein, His Tag
LA3-M52H5-structure
LA3-M52H5-sds
LA3-R52H5 Rat Rat LAG3 / CD223 Protein, His Tag
LA3-R52H5-structure
LA3-R52H5-sds
LA3-H5222 Human Human LAG-3 / CD223 Protein, His Tag (MALS verified)
LA3-H5222-structure
LA3-H5222-sds
ACRO Quality

生物活性データの一部

LA3-H82F3-Cell-based assay
LAG-3 FACS

Flow Cytometry assay shows that Biotinylated Human LAG-3, Mouse IgG2a Fc,Avitag (Cat. No. LA3-H82F3) can bind to daudi cell surface. The concentration of LAG-3 used is 0.3 μg/mL (Routinely tested).

Protocol
LA3-H52Aa-Cell-based assay
LAG-3 FACS

Flow Cytometry assay shows that Human LAG3, Mouse IgG2a Fc Tag (Cat. No. LA3-H52Aa) can bind to daudi cell surface. The concentration of LAG3 used is 0.3 μg/mL (Routinely tested).

Protocol
LA3-H5222-SPR
LAG-3 SPR

Anti-LAG-3 MAb (Human IgG1) captured on CM5 chip via Anti-Human IgG Fc antibodies surface, can bind Human LAG-3, His Tag (Cat. No. LA3-H5222) with an affinity constant of 4.57 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Protocol
LA3-H5222-BLI
LAG-3 BLI

Loaded Anti-LAG-3 MAb (Human IgG1) on AHC Biosensor, can bind Human LAG-3, His Tag (Cat. No. LA3-H5222) with an affinity constant of 7.47 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol

カスタマーレビュー

Synonym Name

LAG3,CD223,FDC

Background

Lymphocyte activation gene 3 protein (LAG3) is also known as CD antigen CD223 and protein FDC, which belongs to immunoglobulin (Ig) superfamily and contains 4 extracellular Ig-like domains. The LAG3 gene contains 8 exons. The sequence data, exon/intron organization, and chromosomal localization all indicate a close relationship of LAG3 to CD4. LAG3 /CD223 involved in lymphocyte activation. LAG3 /CD223 binds to HLA class-II antigens.

Clinical and Translational Updates

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Nivolumab/Relatlimab BMS-986213; BMS-936558/BMS-986016 Approved Bristol-Myers Squibb Company OPDUALAG United States Melanoma Bristol-Myers Squibb Company 2022-03-18 Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Merkel Cell; Colorectal Neoplasms; Melanoma Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Relatlimab ONO-4482; BMS-986016 Phase 3 Clinical Bristol-Myers Squibb Company Urogenital Neoplasms; Female Urogenital Diseases; Urinary Bladder Neoplasms; Brain Neoplasms; Sarcoma; Urinary Bladder Diseases; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Gliosarcoma; Urologic Neoplasms; Urologic Diseases; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Melanoma; Carcinoma, Hepatocellular; Adenocarcinoma; Male Urogenital Diseases; Carcinoma, Non-Small-Cell Lung; Large intestine neoplasm; Glioblastoma; Female Urogenital Diseases and Pregnancy Complications; Hematologic Neoplasms; Carcinoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Solid tumours; Nasopharyngeal Neoplasms; Carcinoma, Transitional Cell; Hodgkin Disease; Carcinoma, Medullary; Multiple Myeloma; Microsatellite instability-high cancer; Uveal melanoma; Chordoma Details
Eftilagimod alpha hLAG-3Ig; CD-223; EDP-202; EOC-202; IMP-321 Phase 3 Clinical Immutep, Prima Biomed Ltd Solid tumours; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Neoplasms; Breast Neoplasms; Sarcoma; Peritoneal Neoplasms; Metastatic breast cancer; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Fianlimab REGN-3767 Phase 3 Clinical Regeneron Pharmaceuticals Inc Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma Details
Tebotelimab PD-1 X LAG-3; MGD-013 Phase 3 Clinical Macrogenics Inc Triple Negative Breast Neoplasms; Adenocarcinoma; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis; Endometrial Neoplasms; Cholangiocarcinoma; Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Liver Neoplasms; Biliary Tract Neoplasms; Hematologic Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms Details
Mavezelimab/Pembrolizumab MK-4280A; MK-4820A Phase 3 Clinical Msd Ireland (Carlow) Merck Sharp & Dohme Corp, MSD R&D（China）Co Ltd Solid tumours; Carcinoma, Renal Cell; Hodgkin Disease; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Squamous Cell; Endometrial Neoplasms Details
SHR-1802 SHR-1802 Phase 2 Clinical Suzhou Suncadia Biopharmaceuticals Co Ltd, Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd Solid tumours; Neoplasms Details
Tobemstomig RO-7247669 Phase 2 Clinical F. Hoffmann-La Roche Ltd Solid tumours; Liver Neoplasms; Carcinoma; Carcinoma, Renal Cell; Neoplasms; Carcinoma, Transitional Cell; Breast Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
Tuparstobart INCAGN-02385; INCAGN-2385 Phase 2 Clinical Agenus Inc, Incyte Corp Head and Neck Neoplasms; Lymphoma, B-Cell; Carcinoma, Merkel Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Melanoma Details
LBL-007 LBL-007 Phase 2 Clinical Leads Biolabs Inc, Nanjing Leads Biolabs Co Ltd Head and Neck Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Neoplasms; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Lymphoma; Carcinoma, Non-Small-Cell Lung; Melanoma Details
Negalstobart IBI-110 Phase 2 Clinical Innovent Biologics(Suzhou) Co Ltd Hematologic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Small Cell Lung Carcinoma; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Small Cell; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Mavezelimab MK-4280 Phase 2 Clinical Merck Sharp & Dohme Corp Lymphoma, B-Cell; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Hodgkin Disease; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung Details
Ieramilimab IMP-701; LAG-525 Phase 2 Clinical Immutep Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Large B-Cell, Diffuse; Prostatic Neoplasms, Castration-Resistant; Sarcoma; Esophageal adenocarcinoma; Melanoma; Persistent Fetal Circulation Syndrome Details
Miptenalimab BI-754111 Phase 2 Clinical C.H. Boehringer Sohn Ag & Co. Kg Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details
FS 118 FS-118 Phase 2 Clinical Merck Serono, F-Star Squamous Cell Carcinoma of Head and Neck; Neoplasms; Neoplasm Metastasis Details
HLX-26 HLX-26 Phase 2 Clinical Shanghai Henlius Biologics Co Ltd Solid tumours; Colorectal Neoplasms; Lymphoma; Carcinoma, Non-Small-Cell Lung Details
GLS-012 GLS-012 Phase 2 Clinical Harbin Gloria Pharmaceuticals Co Ltd Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung Details
EMB-02 EMB-02 Phase 2 Clinical Shanghai Epimab Biotherapeutics, Inc Solid tumours Details
DNV-3 DNV3; DNV-3 Phase 2 Clinical Zhejiang Shimai Pharmaceutical Co Ltd Solid tumours; Neoplasms; Skin Neoplasms; Lymphoma Details
GSK-2831781 IMP-731; GSK‘-781; GSK-2831781; ImmuTune-IMP731 Phase 1 Clinical Prima Biomed Ltd Psoriasis; Colitis, Ulcerative Details
KL-A289 KL-A289 Phase 1 Clinical Sichuan Kelun-Biotech Biopharmaceutical Co Ltd, Anyuan Pharmaceutical Technology (Shanghai) Co Ltd Solid tumours Details
Bavunalimab XmAb-22841; XmAb-841 Phase 1 Clinical Xencor Inc Cholangiocarcinoma; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Fallopian Tube Neoplasms; Penile Neoplasms; Endometrial Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Prostatic Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck Details
Sym-022 Sym-022; Sym022; S95017 Phase 1 Clinical Symphogen A/S Solid tumours; Lymphoma; Neoplasm Metastasis Details
MIL-98 MIL-98 Phase 1 Clinical Beijing Mabworks Biotech Co Ltd Solid tumours; Breast Neoplasms; Lymphoma; Melanoma Details
ABL-501 ABL-501 Phase 1 Clinical Abl Bio Inc Solid tumours Details
ZGGS-15 ZGGS15; ZGGS-15 Phase 1 Clinical Suzhou Zelgen Biopharmaceuticals Co Ltd Solid tumours Details
INCA-32459 INCA-32459 Phase 1 Clinical Incyte Corp, Merus Nv Neoplasms Details
AK-129 AK-129 Phase 1 Clinical Zhongshan Akeso Biopharma Co Ltd Neoplasms; Hodgkin Disease Details
IBI-323(Innovent Biologics) IBI-323 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours; Neoplasms Details
Encelimab TSR-033; TSR 033; TSR033; GSK-4074386 Phase 1 Clinical Anaptysbio Inc Neoplasms Details

This web search service is supported by Google Inc.

totopphone
Call us
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
日本：+(0)81-50-547-99099
Email
メールアドレス
order.jp@acrobiosystems.com
Fax
ファックス
+1 888-377-6111
Address
株式会社アクロバイオシステムズ
〒157-0066
東京都世田谷区成城1丁目26番9-101号

アクロバイオシステムズの公式アカウント

linkedin twitter facebook youtube

お問い合わせ（半角英文字で入力してください）

Copyright © 2017 ACROBiosystems. All Rights Reserved
Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap